Collaborative Group on Hormonal Factors in Breast C (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168
Chlebowski RT, Anderson GL, Aragaki AK et al (2020) Association of Menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA 324(4):369–380
Article CAS PubMed PubMed Central Google Scholar
The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273(3):199–208
Herrington DM, Reboussin DM, Brosnihan KB et al (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343(8):522–529
Article CAS PubMed Google Scholar
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345(17):1243–1249
Article CAS PubMed Google Scholar
Schierbeck LL, Rejnmark L, Tofteng CL et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409
Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P (2014) Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 121(6):700–705; discussion 5
Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol 1(3):296–305
Article PubMed PubMed Central Google Scholar
Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13):1353–1368
Article CAS PubMed Google Scholar
Gartlehner G, Patel SV, Feltner C et al (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force. JAMA 318(22):2234–2249
Hemminki E, McPherson K (1997) Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 315(7101):149–153
Article CAS PubMed PubMed Central Google Scholar
Hodis HN, Mack WJ, Lobo RA et al (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135(11): 939–953
Speroff L, Rowan J, Symons J, Genant H, Wilborn W (1996) The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study) A randomized controlled trial. JAMA 276(17):1397–1403
Article CAS PubMed Google Scholar
Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M (1990) Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 76(4):579–584
Gallagher JC, Kable WT, Goldgar D (1991) Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 90(2):171–178
Article CAS PubMed Google Scholar
Waters DD, Alderman EL, Hsia J et al (2002) Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288(19):2432–2440
Article CAS PubMed Google Scholar
Greenspan SL, Resnick NM, Parker RA (2005) The effect of hormone replacement on physical performance in community-dwelling elderly women. Am J Med 118(11):1232–1239
Article CAS PubMed Google Scholar
Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657
Article CAS PubMed Google Scholar
Bradburn MJ, Deeks JJ, Berlin JA, Russell LA (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26(1):53–77
Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23(9):1351–1375
Hirji KF, Mehta CR, Patel NR (1987) Computing distributions for exact logistic regression. J Am Stat Assoc 82:1110–1117
Chlebowski RT, Anderson G, Manson JE et al (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28(16):2690–2697
Article PubMed PubMed Central Google Scholar
Anderson GL, Chlebowski RT, Aragaki AK et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 13(5):476–486
Article CAS PubMed PubMed Central Google Scholar
Dauphine C, Moazzez A, Neal JC, Chlebowski RT, Ozao-Choy J (2020) Single hormone receptor-positive breast cancers have distinct characteristics and survival. Ann Surg Oncol 27(12):4687–4694
Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662
Article CAS PubMed Google Scholar
Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283–290
Article CAS PubMed Google Scholar
Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99(9):727–737
Article CAS PubMed Google Scholar
Cuzick J, Sestak I, Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880):1827–1834
Article CAS PubMed PubMed Central Google Scholar
Cuzick J, Sestak I, Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67–75
Article CAS PubMed PubMed Central Google Scholar
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M (2019) Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA 322(9):868–886
Chlebowski RT, Aragaki AK (2023) The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause 30(4):454–461
Santen RJ, Stuenkel CA, Yue W (2022) Mechanistic effects of estrogens on breast cancer. Cancer J 28(3):224–240
Article CAS PubMed Google Scholar
Jordan VC, Ford LG (2011) Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila) 4(5):633–637
Article CAS PubMed Google Scholar
Abderrahman B, Jordan VC (2022) Estrogen for the treatment and prevention of breast cancer: a tale of 2 Karnofsky lectures. Cancer J 28(3):163–168
Article CAS PubMed PubMed Central Google Scholar
Santen RJ, Yue W (2019) Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women’s Health Initiative study. Climacteric 22(1):3–12
Article CAS PubMed Google Scholar
Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302(7):774–780
Article CAS PubMed PubMed Central Google Scholar
Beral V, Reeves G, Bull D, Green J, Million Women Study C (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4):296–305
Beral V, Peto R, Pirie K, Reeves G (2019) Menopausal hormone therapy and 20-year breast cancer mortality. Lancet 394(10204):1139
Manson JE, Aragaki AK, Rossouw JE et al (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 318(10):927–938
Article PubMed PubMed Central Google Scholar
Prentice RL, Aragaki AK, Chlebowski RT et al (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 190(3):365–375
留言 (0)